Can I Take Green Tea Extract (EGCG) with NMN or NR?

What Happens When EGCG and NMN/NR Are Taken Together?

Combining EGCG and NMN or NR does not produce a single dramatic interaction. The concern is the sum of two independent biological burdens placed on the liver at the same time. EGCG at high doses stresses hepatic mitochondria directly, while NMN and NR drive NAD synthesis through pathways that also rely on hepatic enzymatic capacity. Taking both together at high doses may push total hepatic load past a threshold that neither supplement would reach alone.

The Pharmacokinetic Side: CYP1A2 Inhibition

EGCG is a moderate inhibitor of cytochrome P450 1A2 (CYP1A2) [1]. CYP1A2 is not the primary route of NMN or NR metabolism, so a direct pharmacokinetic clash is unlikely to be clinically significant for most users. NMN is dephosphorylated to nicotinamide riboside in the gut and then absorbed; NR enters cells via equilibrative nucleoside transporters before conversion to NAD+ [2]. Neither pathway depends heavily on CYP1A2.

EGCG also weakly inhibits CYP3A4 and CYP2C9 at higher concentrations [1]. If you take other medications metabolized by those enzymes alongside both supplements, the interaction picture becomes more complicated and a prescribing pharmacist or physician should review the full list.

The Pharmacodynamic Side: Shared Hepatic Oxidative Load

At doses above 800 mg/day, EGCG has been shown in animal models and human case reports to generate reactive oxygen species within hepatic mitochondria rather than scavenging them [3]. A 2021 analysis published in Antioxidants confirmed that the pro-oxidant versus antioxidant switch for EGCG is dose-dependent, with the inflection point appearing somewhere between 400 and 600 mg of isolated EGCG per day [3].

NMN and NR, by contrast, support mitochondrial health by restoring NAD+ pools. In the phase I trial by Dollerup et al. (N=40), NR at 2,000 mg/day for 12 weeks produced no clinically significant changes in ALT, AST, or bilirubin [4]. That is reassuring, but it does not mean the liver experiences zero additional metabolic demand from high-dose NAD-precursor supplementation.

The pharmacodynamic concern, then, is not that NMN/NR is toxic. It is that EGCG-induced hepatic stress may be harder for the liver to resolve when it is simultaneously handling elevated NAD-synthesis flux.

What Does the Evidence Say About EGCG Hepatotoxicity?

EGCG-induced liver injury is the most well-documented safety signal in the green tea extract literature and the main reason this combination deserves attention.

Case Reports and Systematic Evidence

The U.S. Pharmacopeia reviewed 216 case reports of green tea extract-associated hepatotoxicity through 2008 and concluded the evidence was sufficient to add a cautionary warning to the monograph [5]. A 2020 systematic review by Mazzanti et al. Identified 80 published cases of hepatotoxicity attributed to green tea preparations, with EGCG identified as the likely active agent in the majority of cases [6].

The European Food Safety Authority (EFSA) issued a formal opinion in 2018 setting a safe upper level of 338 mg of EGCG per day from supplements, noting that doses above 800 mg/day were associated with "a transient increase in serum ALT activity" in two randomized controlled trials [7]. The FDA has not set a formal tolerable upper limit but has received MedWatch reports linking concentrated green tea extract supplements to acute liver injury [5].

Why Fasted Dosing Makes Things Worse

One underappreciated finding from the EFSA review is that EGCG hepatotoxicity risk appears substantially higher when the supplement is taken in a fasted state [7]. A 2014 crossover study (N=18) found that peak EGCG plasma concentrations (C-max) were 3.5-fold higher after fasted administration compared with fed administration [8]. Higher peak concentrations mean higher intra-hepatic EGCG concentrations and a greater pro-oxidant burden. Taking EGCG with food is not just a comfort suggestion; it is a pharmacokinetic intervention that meaningfully reduces peak exposure.

NMN/NR's Own Liver Safety Record

The liver safety record for NMN and NR at doses used in clinical trials is reassuring. The first in-human NMN trial by Irie et al. (N=10) tested single oral doses up to 500 mg and reported no adverse changes in liver enzymes, vital signs, or hematologic parameters at any dose [9]. A longer-term study by Yi et al. (N=80) administering NMN at 300 mg/day for 60 days similarly found no hepatic signal [10]. The safety floor is not zero risk at any conceivable dose, but the published data through 2024 do not reveal an intrinsic hepatotoxicity pattern for NMN or NR.

How Much EGCG Is Actually in Common Products?

Understanding real-world doses matters because the danger zone identified by EFSA (above 338 mg EGCG/day) is easier to cross than most users realize.

Green Tea Beverages vs. Supplements

A standard brewed cup of green tea contains roughly 50-100 mg of EGCG depending on brewing time, water temperature, and leaf grade [11]. Drinking three to four cups a day keeps most people well below the EFSA threshold. The risk rises sharply with concentrated capsule or powder products marketed for weight loss, metabolic support, or antioxidant effects.

Popular standardized green tea extract supplements on the market deliver anywhere from 200 mg to 1,000 mg of EGCG per serving. Products standardized to 50% EGCG with a 500-mg capsule deliver 250 mg per dose; two capsules push you to 500 mg, already above the EFSA ceiling.

Synergistic Supplements That Push the Total Higher

Many NAD-precursor stacks also include resveratrol, quercetin, or other polyphenols. Quercetin is itself a CYP1A2 and CYP3A4 inhibitor [12]. Stacking EGCG with quercetin while taking NMN or NR adds another layer of CYP inhibition that may slow the clearance of all polyphenols simultaneously, prolonging their hepatic exposure time. If your NMN/NR product contains quercetin, consider that before adding any additional green tea extract.

Practical Dosing and Timing Guidance

The following framework is the HealthRX medical team's clinical recommendation, synthesized from the published pharmacokinetic data above. It has not been tested in a prospective trial; it represents a conservative application of available evidence.

The Three-Tier Approach by EGCG Dose

Tier 1: EGCG below 200 mg/day (low risk) This covers most people drinking two to three cups of brewed green tea daily and not using a concentrated supplement. No dose separation is required. Take NMN or NR as you normally would, with or without the tea, and monitor liver enzymes annually as part of routine labs.

Tier 2: EGCG 200-338 mg/day (moderate caution) This is the range typical of one moderate-dose green tea extract capsule per day. Separate the EGCG dose from your NMN/NR dose by at least 30-60 minutes. Take EGCG with food, not fasted. Check ALT and AST at baseline and at three months. If both remain below 1.5 times the upper limit of normal, continuing the combination is reasonable.

Tier 3: EGCG above 338 mg/day (high caution; physician review recommended) At this dose, the EFSA considers the risk of liver enzyme elevation clinically meaningful. Combining doses in this range with NMN/NR without physician oversight is not advisable. If a clinician approves the combination, a 60-minute separation window, fed-state dosing of EGCG, and quarterly liver enzyme monitoring represent the minimum precautions.

What to Do If You Are Already Taking Both

Stop neither supplement abruptly. Instead, check your current EGCG dose against the Tier framework above and order a basic metabolic panel that includes ALT, AST, alkaline phosphatase, and total bilirubin. If those values are within normal range, step down to Tier 2 or Tier 1 dosing. If any liver enzyme is above 2 times the upper limit of normal, discontinue the EGCG supplement first (green tea extract is the higher-risk agent) and recheck labs in four weeks.

Who Faces the Highest Risk?

Not everyone who combines these supplements has the same baseline hepatic reserve.

Populations That Need Extra Caution

People with non-alcoholic fatty liver disease (NAFLD) already have mitochondrial dysfunction and elevated baseline oxidative stress in hepatocytes [13]. Adding high-dose EGCG to that background increases the risk that the pro-oxidant threshold will be reached at lower absolute doses. A 2019 meta-analysis of green tea supplementation in NAFLD patients (N=263 across five trials) found a statistically significant reduction in ALT with doses below 500 mg/day of green tea extract, but the authors noted that no trial tested doses above 856 mg/day in this population, leaving the upper range uncharacterized [14].

Regular alcohol consumers metabolize acetaldehyde through pathways that also generate reactive oxygen species, compounding any EGCG-mediated oxidative load. The combination of alcohol, high-dose EGCG, and an NAD-precursor supplement in someone with fatty liver represents the highest-risk scenario described in this article.

People taking acetaminophen regularly face a separate concern: CYP1A2 inhibition by EGCG can subtly alter acetaminophen metabolism, though the clinical significance of this interaction at typical OTC doses is considered minor [1].

Populations Where the Combination Looks Safer

Young adults with no liver disease, no alcohol use, and EGCG doses below 200 mg/day from food sources (brewed tea) appear to face negligible added risk when starting NMN or NR. The clinical trial data for NMN and NR in healthy adults are uniformly reassuring at doses up to 1,200 mg/day [9, 10].

Monitoring Protocol for Concurrent Use

Routine lab monitoring is the practical safeguard that allows this combination to be used with confidence in appropriate patients.

Recommended Lab Panel

Order a hepatic function panel at baseline before starting either supplement. The panel should include ALT, AST, alkaline phosphatase, gamma-glutamyl transferase (GGT), and total bilirubin. Recheck at six weeks and three months after initiating the combination.

The stopping rule used in most supplement hepatotoxicity monitoring programs is an ALT or AST rise above three times the upper limit of normal confirmed on two measurements at least one week apart [15]. If either value crosses that threshold, discontinue EGCG first and recheck in 30 days. If values normalize, EGCG was the likely driver. If values remain elevated after EGCG discontinuation, consult a hepatologist.

Symptom-Based Warning Signs

Do not wait for scheduled labs if any of the following appear: jaundice (yellowing of skin or eyes), right upper quadrant pain, dark urine, severe fatigue, or nausea lasting more than 48 hours. These may indicate acute liver injury. Seek medical evaluation promptly.

Does EGCG Affect NAD+ Levels Directly?

One question that arises in longevity supplement circles is whether EGCG actively interferes with NAD+ biosynthesis rather than just straining the liver.

CD38 Inhibition: A Potential Benefit

CD38 is an NAD+-consuming enzyme whose activity increases with age and inflammation. EGCG has been shown to inhibit CD38 in cell culture studies, which in principle could preserve endogenous NAD+ levels [16]. A 2020 study published in GeroScience demonstrated that several polyphenols including EGCG reduce CD38 activity in murine tissues, resulting in measurable NAD+ increases without exogenous NAD precursor supplementation [16].

If that effect translates to humans at achievable oral doses, EGCG and NMN/NR might actually work together toward the same NAD+ goal through complementary mechanisms, one adding precursor substrate and the other reducing NAD+ consumption.

The Dose Problem

The EGCG concentrations used in the CD38 cell-culture studies are typically 10-100 micromolar, which is difficult to achieve in human plasma at safe oral doses [16]. Oral EGCG at 400 mg produces peak plasma concentrations in the range of 1-2 micromolar in most pharmacokinetic studies [8]. The CD38 inhibition story is biologically interesting but has not yet been confirmed in a human trial measuring both EGCG plasma levels and whole-blood NAD+ simultaneously.

Key Drug and Supplement Interactions to Know

Beyond the NMN/NR interaction itself, EGCG interacts with several other common agents.

Medications Metabolized by CYP1A2

EGCG's inhibition of CYP1A2 is most relevant for substrates with a narrow therapeutic index: clozapine, theophylline, tizanidine, and erlotinib [1]. If you take any of these medications, adding high-dose EGCG without physician review is not appropriate. Clozapine levels, for example, may rise 20-40% with strong CYP1A2 inhibition, a change large enough to produce toxicity [1].

Iron Absorption

EGCG chelates non-heme iron in the gut and can reduce iron absorption by up to 25% when taken with an iron-rich meal [17]. People with iron-deficiency anemia or who take iron supplements should separate EGCG from iron by at least two hours.

Anticoagulants

High-dose green tea extract may have mild anti-platelet effects. While the interaction with warfarin is considered minor at typical doses, INR monitoring is advisable for anticoagulated patients who add concentrated EGCG to their regimen [17].